RBC Capital began covering Solid Biosciences LLC (SLDB) with an Outperform rating on September 16, 2026.
The past 90 days include five active firms, with five rating the stock bullish. As of October 30, 2026, 16 analysts place the consensus mean at $19.30, the median at $18.36 and the range at $14.14 to $27.30.
Consensus Q4 FY2026 EPS is -$0.44, with revenue at $0. The next earnings report is on March 4, 2027.
